共 50 条
- [1] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090SSandler, ABGray, RBrahmer, JDowlati, ASchiller, JHPerry, MCJohnson, DH
- [2] Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 370S - 370SDowlati, A.Gray, R.Johnson, D. H.Schiller, J. H.Brahmer, J.Sandler, A. B.
- [3] Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) : 1416 - 1423Sandler, AlanYi, JingDahlberg, SuzanneKolb, Margaret M.Wang, LisaHambleton, JulieSchiller, JoanJohnson, David H.
- [4] E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Argiris, AthanassiosLee, Ju-WheiStevenson, JamesSulecki, Matthew GerardHugec, VladimirChoong, Nicholas W.Saltzman, Joel N.Song, WeiHansen, Richard M.Evans, Tracey L.Ramalingam, Suresh S.Schiller, Joan H.
- [5] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698Guarino, Michael J.Masters, Gregory A.Biggs, David D.
- [6] Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 studyJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Ramalingam, S. S.Dahlberg, S. E.Langer, C. J.Gray, R.Belani, C. P.Brahmer, J. R.Sandler, A.Schiller, J. H.Johnson, D. H.
- [7] Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 studyJOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S468 - S468Ramalingam, Suresh S.Dahlberg, Suzanne E.Langer, Corey J.Gray, RobertBelani, Chandra P.Brahmer, Julie R.Sandler, AlanSchiller, Joan H.Johnson, David H.
- [8] Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)ANNALS OF ONCOLOGY, 2017, 28 (12) : 3037 - 3043Argiris, A.Lee, J. W.Stevenson, J.Sulecki, M. G.Hugec, V.Choong, N. W.Saltzman, J. N.Song, W.Hansen, R. M.Evans, T. L.Ramalingam, S. S.Schiller, J. H.
- [9] Sex Differences in Outcome with Bevacizumab Therapy Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 103 - 108Brahmer, Julie R.Dahlberg, Suzanne E.Gray, Robert J.Schiller, Joan H.Perry, Michael C.Sandler, AlanJohnson, David H.
- [10] Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) : 418 - 423Langer, CoreyLi, SiguiSchiller, JoanTester, WilliamRapoport, Bernardo L.Johnson, David H.